Trulieve Cannabis is trading at $11.44 (+4.05%), with no clear company-specific catalyst identified for the after-hours rise. - Reporting says the DEA rescheduling proceeding remains stayed while the agency responds to a motion concerning reopening the hearing. - Major U.S. indices were higher on October 21, supporting a broader risk-on backdrop, but reporting does not establish that sentiment caused this move. Consumer staples were down after hours, making the provided sector context directionally inconsistent.